Protalix BioTherapeutics Public
Protalix BioTherapeutics is a biopharmaceutical company that specializes in the development and manufacturing of recombinant therapeutic proteins. They have revolutionized the industry through their ProCellEx® plant cell-based protein expression system. Their main goal is to develop and commercialize a pipeline of novel and biosimilar proteins that target genetic disorders and inflammatory diseases. Protalix's achievements include the approval of their first FDA-approved plant cell-based recombinant therapeutic protein, ELELYSO™, for the treatment of Gaucher disease. They have also partnered with Pfizer for the worldwide development and commercialization of ELELYSO.
Investors
Industry:
PharmTech
Investors Number:
1
Technology:
Drug development
Last Funding Type:
Seed
Headquarters:
Carmiel, HaZafon, Israel
Founded Date:
1994-01-01
Funding Status:
IPO
Total Funding:
$10.8M
Estimated Revenue:
$10M to $50M
Employee Number:
501-1000